Our preclinical suggests that ABT-737 enhanced BIM expression in NSCLC cells containing EGFR-mutant, whether it was BIM-wild type or BIM deletion polymorphism. This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.